Related Experiment Videos

Thapsigargin enhances camptothecin-induced apoptosis in cardiomyocytes

J Y Kong1, S W Rabkin

  • 1University of British Columbia, Vancouver, Canada.

Pharmacology & Toxicology
|December 23, 1999
PubMed

Insights

Camptothecin, a topoisomerase I inhibitor, induces apoptosis in cardiomyocytes. Thapsigargin enhances this cell death, suggesting calcium regulation influences camptothecin cardiotoxicity.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Topoisomerase I inhibitors are emerging chemotherapeutics for malignancies.
  • Cardiomyocytes are susceptible to drug-induced cell death.
  • Calcium flux plays a role in cellular homeostasis and apoptosis.

Purpose of the Study:

  • Investigate camptothecin's effect on cardiomyocyte cell death.
  • Determine if thapsigargin modulates camptothecin-induced apoptosis.
  • Elucidate the role of calcium in camptothecin's cardiotoxicity.

Main Methods:

  • Cardiomyocytes cultured from embryonic chick hearts.
  • Cell viability assessed by trypan blue and MTT assays.
  • Apoptosis confirmed by DNA fragmentation analysis and flow cytometry.

Main Results:

  • Camptothecin induced dose-dependent apoptosis in cardiomyocytes.
  • Thapsigargin pretreatment significantly augmented camptothecin-induced apoptosis.
  • EGTA, a calcium chelator, reduced camptothecin-induced DNA fragmentation.

Conclusions:

  • Camptothecin exhibits potential cardiotoxicity via apoptosis.
  • Agents affecting calcium regulation can enhance camptothecin-induced apoptosis.
  • Understanding calcium's role is crucial for managing camptothecin therapy.

Related Concept Videos